Celea Therapeutics to present SURPASS-IPF Phase 3 trial design at IPF Summit 2026

The company said it will present two posters on its deupirfenidone program at the IPF Summit in Boston on Sept. 29-Oct. 1, 2026. It said SURPASS-IPF is a global Phase 3 head-to-head trial of deupirfenidone versus pirfenidone in about 1,100 adults with idiopathic pulmonary fibrosis.